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Background {#s1}
==========

Signal transduction contains cluses to how abberation in cancer cells may lead to uncontrolled growth and division. It has been hypothesized that evidence of functional signal transduction can be found by examining the mRNA expression-based correlation structure of known ligand-receptor pairs (LRPs) [@pone.0107193-Graeber1]. If correlation is found between a pair, one infers that they form a positive-feedback loop, an autocrine signaling relationship.

A survey in 2006 examined autocrine signaling pairs in epithelial ovarian cancer (EOC) [@pone.0107193-Castellano1] and confirmed their findings by immunohistochemical staining. Importantly, this study continued to develop the idea that differential signaling (a change in autocrine status) might be associated with prognosis.

Statistical differential correlation or differential co-expression (DC) techniques have advanced significantly in recent years allowing for the consideration of multivariate associations beyond treating LRPs one at a time [@pone.0107193-Shedden1]. For example, a Gaussian graphical model (GGM) studies the precision matrix (the inverse of the correlation) to infer signaling and statistical work has developed techniques for proper false discovery control [@pone.0107193-Schfer1]. Recently, it has been proposed to directly estimate the difference in precision matrices to study differential signaling [@pone.0107193-Zhao1].

Combining new correlation techniques with the foreknowledge of candidate signaling pairs derived from protein folding models and confirmatory biochemical experiments [@pone.0107193-Kanehisa1], we conjectured that a multivariate survey may yield better functional understanding of clinically relevant signaling with strong translational potential. We focus on the Cancer Genome Atlas (TCGA) study of ovarian cancer [@pone.0107193-The1] as a discovery set paired with two large, independent studies for validation [@pone.0107193-Tothill1], [@pone.0107193-Yoshihara1]. Our plan is an update of the study conducted by Castellano *et al*. (n = 522) in that each of the new datasets totals over 500 patients and comprise a more clinically relevant set -- a higher percentage of high-grade EOC and long follow up periods -- each conducted as single study instead of several small studies.

We augment the autocrine signaling hypothesis with similar correlation-based models of cancer-relevant signal transduction. Zandi and colleagues reviewed a number of modes of deleterious signaling in the EGFR family of transmembrane receptors [@pone.0107193-Zandi1], relevant to expression data are: the overexpression of the ligand, the overexpression of the receptor, and receptor-receptor crosstalk. In addition to DC analysis, we consider whether the interaction term in a survival regression model can detect an association directly. Finally, we consider whether prognostic LRPs vary over time and heterogenously across patients.

Methods {#s2}
=======

Ligand-Receptor Pair Database {#s2a}
-----------------------------

We identified interacting pairs from the Database of Ligand-Receptor Partners (DLRP, <http://dip.doe-mbi.ucla.edu/> [@pone.0107193-Graeber1]), matching 162 ligands, 131 receptors and 419 paired interactions on the Affymetrix array. We augmented this set with KEGG pathways [@pone.0107193-Kanehisa1] hsa04060 (Cytokines/Chemokines) hsa04512 (Cell adhesion molecules) and hsa04514 (ECM interactions). In total, there are 475 pairs (200 ligands, 166 receptors) for consideration after verifying the ligand/receptor functions ([Table S1](#pone.0107193.s001){ref-type="supplementary-material"}).

Expression and Clinical Data {#s2b}
----------------------------

Correlation and survival analysis depend on 503 TCGA samples [@pone.0107193-The1] ([Table S2](#pone.0107193.s002){ref-type="supplementary-material"}) and 500 validation samples collected from two studies by Tothill and colleagues [@pone.0107193-Tothill1] and Yoshihara and colleagues [@pone.0107193-Yoshihara1]. In each study, measurements are made on tumor tissue excised during surgery prior to chemotherapy. Expression is measured on Affymetrix\'s HT-HG-U133A and HG-U133 Plus 2.0 arrays (GPL570, GPL571) for the TCGA and Tothill (GSE9899) studies as well as an Agilent platform (GPL56480). Notably the TCGA study uses 3 independent platforms, we opted to analyze just the U133A assay as it was most complete at the time of data acquisition. We follow the standard RMA [@pone.0107193-Irizarry1] algorithm and further reduce data to gene level measurements by the brightest-spot rule. Standard gene names are then matched across platforms.

While TCGA samples are selected for advanced serous EOC, Tothill\'s study contains a representative number of endometriod subtypes; cases with low maligant potential are omitted. Yoshihara\'s dataset are strictly high-grade, high-stage ovarian cancers. Further, the rate of optimal debulking surgeries is high in the Yoshihara data set (40% vs. 23% p, [Table 1](#pone-0107193-t001){ref-type="table"}). Beyond this difference, these patients all undergo debulking surgery and adjuvant platinum-based chemotherapy as standard treatment.

10.1371/journal.pone.0107193.t001

###### Clinical differences between discovery and validation studies.

![](pone.0107193.t001){#pone-0107193-t001-1}

                                Studies                
  --------------- ------------ --------- ------ ------ -----------------------------------
  N                               503     240    260   
  Age                 Mean       59.8     60.2    NA   
  Stage              I, II        24       9      0    
                    III, IV       463     215    260    [\*](#nt101){ref-type="table-fn"}
  Grade                1           4       5      0    
                      2,3         473     218    260                  \*\*
  Cytoreduction     Optimal       102      53    103   
                   Suboptimal     348     140    157    [+](#nt102){ref-type="table-fn"}
  Follow Up                                            
  OS                 Median       30       28    41.5  
  PFS                Median      13.2      14     19   

\*excludes Yoshihara data, p-value  = .001597 when including Yoshihara data.

definition of optimal/suboptimal not clearly defined in Yoshihara data.

We have focused on progression-free survival (PFS) instead of overall survival as post-recurrence treatments are varied and will confound the genetic signals apparent in pre-treatment tissue. Below, we will stratify patients based on PFS to 18 months, the typical median time to progression for advanced EOC [@pone.0107193-Vaughan1]. This is a clinically meaningful endpoint as patients who progress after this time will typically be called "platinum sensitive" and will receive a second regimen of platinum (and taxane) chemotherapy. Standard treatment for patients who recur before this interval is uncertain.

Models and Hypotheses {#s2c}
---------------------

We summarize the various LRP models to be tested. Each of these models will have its own specialized analysis. Throughout the paper, we will refer to a specific LRP as LigandReceptor to emphasize the pairing.

-   **Model 1**. Correlation of ligand-receptor pair expression implies autocrine signaling. [@pone.0107193-Graeber1]

-   **Model 2**. Correlation in short PFS subset and lack of or inverse correlation in long PFS subset implies prognostic autocrine signaling. [@pone.0107193-Castellano1]

-   **Model 3**. Significant statistical interactions crossed by correlated sets should imply functionally relevant signaling.

-   **Model 4**. Receptor-Receptor correlation implies receptor cross-talk or heterodimerization. [@pone.0107193-Zandi1]

Correlation Models {#s2d}
------------------

We compute Pearson\'s correlation between the expression of ligand and receptor genes. Significance tests are based on the statistic that follows a t-distribution with n-2 degrees of freedom [@pone.0107193-Best1]. Note that correlation is invariant to scaling and centering. To account for the effect of outliers, we performed a sensitivity analysis using Spearman\'s rank correlation (the effect of a small number of outliers will be attenuated). Our results did not change substantially.

Differential correlation is based on stratifying patients into long PFS intervals (PFS 18 months) and short PFS intervals. Patients censored prior to 18 months are excluded from analysis, because these patients have insufficient followup to positively identify them into a long or short response; that is, patients who are known to recur before 18 months are assigned to the short interval group. There are 227 long PFS intervals and 186 short in the TCGA study. For each LRP, we computed correlation in each set separately (Bonferroni ) and classified pairs as "both" if long and short PFS sets have significant differences. We imagine that the long PFS subset represents nominal function, so that if a pair is correlated in the long PFS set and not in the short PFS set, we say the effect is a "loss" of function. Conversely, if a set is correlated in the short PFS set and not in the long PFS set we say the effect is a "gain" of deleterious function.

Survival regression models {#s2e}
--------------------------

For each LRP, we regressed PFS on a set of candidate Cox proportional hazards regression models. In these models, the Ligand and Receptor may act additively or may interact. We selected the model maximizing Akaike\'s Information Criterion for each pair, classifying them as simply additive or synergistic if the interaction term was significant. We considered both scaled and centered data and expression rescaled to quantiles so that the hazard ratios have a more consistent interpretation. Again, the quantile scale reduces the potential effect of outliers.

Partial correlation for receptor crosstalk models {#s2f}
-------------------------------------------------

We estimated the Gaussian graphical model (GGM) via the GeneNet algorithm with edge posterior probability 0.90 [@pone.0107193-Schfer1], again stratifying patients into long and short PFS subsets. Edges that appear in both sets are classified as functional but not specific to prognosis, edges specific to the short survivors are termed "gain of function" and the edges specific to the long survivors are termed "loss of function." We harmonized the estimated graphs by combining them with significant LRPs selected through the DC analysis. The graphical layout was done by hand aiming to emphasize clarity and size of the contiguous networks.

Heterogeneity and predictive models {#s2g}
-----------------------------------

Our analysis so far assumes homogeneity in time and across patients. We attempt to relax the first by noting that the DC analysis requires us to pick a timepoint to define long/short PFS. We vary this threshold across 1 to 60 months and record the change in DC test statistics. This sensitivity analysis highlights the range of time for which a particular signaling pair is relevant for prognosis.

To test homogeneity in signaling pairs across patients, we select only the LRPs from the DC analysis and run a supervised clustering algorithm to detect subgroups [@pone.0107193-Eng1]. This algorithm clusters patients based on having similar survival models. We assigned patients to their *maximum a posteriori* class and computed an importance score: the absolute value of the expression level of the interaction multiplied by the cluster specific regression effect for each patient. Large scores reflect the determination that signaling in this LRP has a large influence on a particular patient\'s prognosis; small values imply little influence.

Results {#s3}
=======

Global correlation and active autocrine signaling {#s3a}
-------------------------------------------------

Following Graeber and Eisenberg\'s hypothesis, we tested for significant correlation between 475 ligand-receptor pairs and found 96 significant pairs in the TCGA discovery set (Bonferroni ). Of these, 77 are reproduced in our validation set with significant correlation and concordant direction of effect ([Table S3](#pone.0107193.s003){ref-type="supplementary-material"}). Using Spearman\'s rank correlation to attenuate the effect of outliers, 70 of the 77 are robust to extreme values. Three pairs have significant negative correlation: INHBAACVR1B, INHBAACVR2B and JAM2F11R. We note that the magnitude of the selected correlations is remarkably strong (median with 13/77, 16% greater than 0.50) which is consistent with previous studies [@pone.0107193-Castellano1]. A list of the full list of significant pairs, their estimated correlation and significance tests in both data sets is included in supplemental material.

For reference, we considered the distribution of sample correlations after permuting the relationship between ligand and receptor. Pairs that were individually significant (p\<0.05) had an average correlation of given the true pairings versus and average for pairs with significant associations given random associations (t-test p = 4.4e-11). If we randomly select 475 transcript pairs from any measured gene, the average effect drops to (t-test p = 2.8e-16). This implies that the average direction and magnitude of the observed LRPs are unlikely to be coincidental.

Ligand-receptor correlation stratified by long/short prognosis {#s3b}
--------------------------------------------------------------

Stratifying patients by long and short PFS, we identify 63 pairs with significant correlation in one or both subgroups. Of these 55 are found to have a significant gain or loss in the validation set. We note in [Figure 1B](#pone-0107193-g001){ref-type="fig"}, that significant correlations are uniformly positive consistent with a positive feedback loop. A pair can have positive or non-significant (n/s) correlation in the (long; short) PFS strata: we classify them as (positive; n/s), a loss of function; (n/s, positive), a gain of function; (positive, positive) functional but not specific to survival.

![Correlation among ligand-receptor pairs.\
(A) Correlation in ligand-receptor pairs (LRPs) in the discovery and validation datasets is largely concordant. (B) Stratified by prognosis, there is evidence of differential correlation. (C) The intersection of correlation and survival regression model interactions suggests that some LRPs are prognostic but not necessarily correlated (not autocrine).](pone.0107193.g001){#pone-0107193-g001}

Using the discovery cohort, the selected set of pairs comprises 39 receptors and 56 ligands ([Table S4](#pone.0107193.s004){ref-type="supplementary-material"}). The most frequently represented receptors are FGFR2, FGFR3, and EPHA5, each with at least 5 connections. While most of the remaining ligands are specific to one receptor (34/39, 87%), CCL13, CCL7, CCL8, FGF9, IL15 each form pairs with 3 receptors. With reference to the findings by Castellano and colleagues [@pone.0107193-Castellano1], we find that in at least one dataset, ENFB2EPHA4 had a gain of function, LIFIL6ST had loss of function and IL15IL2RG had non-specific function. The rest of the pairs had no significant change in correlation in either dataset.

This set is largely concordant with the analysis using all patients together. All pairs labelled with correlation in both sets were previously selected (34 of 63). Three pairs identified by stratified analysis had no significant marginal correlation (JAG2NOTCH3, NGFNGFR, and INHBCACVR2B); these pairs would have been missed without stratification. A significant subset of previously identified pairs were not significant in the stratified analysis (36/96, 38%), likely due to a loss of power due to splitting the sample, implying they are likely lower confidence results.

Ligand-receptor interaction in regression models {#s3c}
------------------------------------------------

No single ligand or single receptor was associated with PFS without considering its paired relationship (Cox regression, Bonferroni-adjusted likelihood ratio test). We subsequently identify significant paired ligands and receptors which supports the hypothesis that signal transduction is associated with survival versus simple overexpression of the ligand or receptor.

Regressing on the quantiles of expression, 29 pairs have selected interaction models ([Table S5](#pone.0107193.s005){ref-type="supplementary-material"}). Of these, 16 have interaction or additive models in the validation cohort. Four have consistent directions of effects across datasets; three of these are in the ephrin family and one is FGF1-FGFR2. If we consider scaled and centered expression data ([Table S6](#pone.0107193.s006){ref-type="supplementary-material"}), 9 pairs are again selected and validated: PDGFAPDGFRA, COL1A1CD44, IFNA14IFNAR2, JAG2NOTCH2, EFNA3EPHA1, EFNB3EPHA4, FGF1FGFR2, VEGFANRP1, and EREGERBB4.

When cross-tabulated by the correlation analysis, most pairs with significant interaction regression models do not have marginal correlation between the ligand and receptor. Thus, we infer the existence of a class of prognostic signaling pairs that operate without an autocrine feedback loop and we hypothesize that these ligand-receptor pairs act on prognosis in a typical endocrine fashion.

Graphical model of receptor crosstalk {#s3d}
-------------------------------------

We considered whether there is evidence of receptor heterodimerization and crosstalk functioning as a mechanism of oncogenic signaling. Continuing to assume that correlation implies signaling cooperativity, we used Gaussian graphical modeling techniques to estimate the graphical edges between receptors. We discovered 29 edges (posterior probability ) between the 39 receptors with significant differential associations from the stratified analysis. These edges are again classified into Loss/Gain/Non-specific function based on whether they are significant in the long PFS strata, the short PFS strata or both; the majority are losses (22/29, 76%) suggesting a breakdown in signaling coincides with poorer outcomes.

[Figure 2](#pone-0107193-g002){ref-type="fig"} connects the active ligand-receptor pairs to one another via cooperating receptors. We see that there is one large network of ephrins, the fibroblast growth factor (FGF), and Notch signaling that, as noted, tends to lose its coherence in the short PFS strata. There exists a small CCR chemokine network that is strongly interconnected (13/18 possible edges) indicating both their promiscuity and potential for a multivariate risk phenotype. Other small graphs include a PDGFR family and VEGF/PGF growth factor family. The remaining receptors operate independently.

![Multivariate correlation graph.\
Connecting all of the validated LRPs to one another via estimated receptor cross-talk shows a mix of small independent graphs and a large single signaling graph. Grey edges are not specific to prognosis; blue edges are gained in poor prognosis patients.](pone.0107193.g002){#pone-0107193-g002}

Heterogeneity in prognostic signaling {#s3e}
-------------------------------------

To study heterogeneity in signaling across patients, we applied a supervised clustering algorithm to identify prognostic, multivariate sets of LRPs. It identifies four subsets of patients defined by the relationship of signaling pairs and PFS visualized in [Figure 3](#pone-0107193-g003){ref-type="fig"}. Patients are arranged by cluster (columns) and LRPs are in rows where LRPs with significant univariate associations with PFS are highlighted.

![Heterogeneity analysis by patient and in time.\
(A) Patient heterogeneity implies four prognosis clusterse driven by different LRPs. (B) Each of these clusters has a distinct prognosis. (C) Over time, there are significant changes in the prognostic association and specific LRPs at about 9 and 27 months, close to the second treatment times for platinum resistant and sensitive patients.](pone.0107193.g003){#pone-0107193-g003}

The first cluster of patients has no relation between signaling and PFS (Cox model ) and has the worst prognosis (13.9 vs 18.0 months median, p = 1.8e-05) likely reflecting the fact that this cluster has the highest rate of patients with progressive disease after primary treatment. The second cluster\'s model has a mild prognostic effect (R^2^ = 0.254, p = 1.0e-06) with 6 significant pairs (PDGFAPDGFRA, COL1ACD44, COMPCD36, FGF9FGFR2, PGFFLT1, INHBAACVR1). Notably, these interactions are differentially expressed between the first and second clusters implying they may be markers for identifying these patients. The third and fourth clusters are strong models (R^2^\>0.600, p\<1e-06 for both) with 7 and 10 significant, mutually exclusive LRPs. Patients in the third cluster have significantly shorter PFS (17.3 months versus 25.1, p = 0.00873). Both the longest and shortest PFS groups contain similar signaling pathways; notably the presence of ephrins and FGF differ between them. The models and their clinical associations are summarized in [Table 2](#pone-0107193-t002){ref-type="table"} with a summary of the drug target relevant signals.

10.1371/journal.pone.0107193.t002

###### Clinical associations for signaling clusters.

![](pone.0107193.t002){#pone-0107193-t002-2}

                                                   Signaling Cluster                                                                                                                             
  ------------------------- --------------------- ------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ------------
  n                                                       101                           186                                      106                                      110                    
  Events                                                  100                            95                                       93                                       73                    
  PFS Model fit                      LRT                 0.281         0.001[\*](#nt103){ref-type="table-fn"}   0.001[\*](#nt103){ref-type="table-fn"}   0.001[\*](#nt103){ref-type="table-fn"}  
                                    R^2^                 0.196                         0.254                                    0.620                                    0.675                   
  Stage                           \% III/IV               93%                           94%                                      91%                                      91%                     p = 0.665
  Grade                            \% 3/4                 86%                           85%                                      80%                                      88%                     p = 0.420
  Clinical                    Complete Response           56                            106                                       62                                       64                    
  Response                    Partial Response            13                             17                                       17                                       12                    
                               Stable Disease              2                             12                                       7                                        5                     
                             Progressive Disease          14                             8                                        6                                        8                     
  Objective Response Rate            68%                  66%                           75%                                      69%                                   p = 0.522                 
  Disease Control Rate               70%                  73%                           81%                                      74%                                   p = 0.292                 
  OS                            Median Months            38.3                           41.0                                     44.8                                     51.9                    p = 0.0875
  PFS                           Median Months            13.9                           16.6                                     17.3                                     25.1                     p\<0.001
  Notable Effects                                        VEGF                           VEGF                                    Immune                                    VEGF                   
                                                         PDGF                           PDGF                                                                              PDGF                   
                                                        Ephrins                         FGF                                                                               FGF                    
                                                         Notch                         TGF*β*                                                                            Notch                   

\*: p-value smaller than 0.001.

OS: Overall survival.

PFS: Progression-free survival.

LRT: Likelihood-ratio test.

Varying the cutpoint for long/short PFS, we considered whether the DC test statistic was sensitive to a particular time range for each LRP ([Figure 3](#pone-0107193-g003){ref-type="fig"}). While all pairs remain significantly DC throughout the range of followup, there are two critical periods where significance drops for several pairs implying they may be more relevant to early followup: at 8.75 months, CCL12CCR7 and CCL8CCR2; and at 26.63 months, CCL13CCR2, CCL7CCR2, and CCL7CCR5. Notably, these times seem to correspond to the median time to initiation of secondary therapies for platinum resistant and platinum sensitive cancers suggesting that these cytokines are related to therapy response.

Discussion {#s4}
==========

We have extended autocrine signaling loop screening techniques to incorporate survival outcomes more comprehensively. We confirmed the association of ephrin family receptors [@pone.0107193-Castellano1] as well as NOTCH signaling [@pone.0107193-The1] with ovarian cancer prognosis. We find a class of LRPs showing autocrine-type correlation but with no effect on survival; these would have been false-positive associations made in previous studies. Conversely, we find a class of LRPs with survival associations that have no significant correlation which implies their nominal function affects prognosis without any system feedback. In addition, we have shown that mutually exclusive sets of LRPs may function in different programs of both gain and loss of signaling function. The connection between these LRPs might be made via correlated changes between receptors and we have estimated the relevant wiring between them.

Drawn from a solely computational analysis, our conclusions are limited to transcriptome-type studies. Two recent concerns with these studies are run batch effects and the influence of tumor purity. We have used multiple large and independent datasets to reproduce candidate signals to alleviate some of these concerns. While a natural next step is to verify that these transcripts are indeed expressed in these tissues, the finding that they are reproducible using similar probes is promising.

In the context of chemotherapy, assessing the prognostic importance of signal transduction is an appealing avenue for biomarker development relevant for ovarian cancers: nearly 75% of cases eventually fail surgical control with primary platinum/taxane adjuvant chemotherapy [@pone.0107193-Vaughan1] and common second-line treatments (gemicitabine [@pone.0107193-Nowak1], topotecan [@pone.0107193-Trojandt1]) show differences in immune effect/response.

We have highlighted three particular receptor tyrosine kinases (VEGFR, PDGFR and FGFR) each of which is targeted individually or in combination by one of a number of inhibitors at various stages of approval [@pone.0107193-Yap1]. Among these compounds are bevacizumab, targeting VEGF signaling [@pone.0107193-Burger1]; sunitinib, targeting VEGF and PDGF; nintedanib targeting all three; and imatinib targeting just PDGFR. The prevalence of these three signaling interactions leads us to conjecture that different patients may respond to therapies targeting different combinations of receptors which might be inferred from expression data.

We conjecture that the prevalence of immune related LRPs in our validated sets and the per patient heterogeneity suggest the potential for an actionable biomarker to distinguish the utility of chemotherapy or immunotherapy treatment strategies. Further, the discovery of so many immune interactions is likely to be representative of the immunogenic nature of ovarian cancers [@pone.0107193-Zhang1] and of chemotherapy; it is a positive control confirmation for this correlation-based approach.
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The results published here are in whole or part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at <http://cancergenome.nih.gov/>.
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